D. E. Shaw & Co., Inc. Scholar Rock Holding Corp Transaction History

D. E. Shaw & Co., Inc.

$122 Billion
Q4 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Scholar Rock Holding Corp stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 666,885 shares of SRRK stock, worth $24.7 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

666,885

Previous 195,774 240.64%

Holding current value

$24.7 Million

Previous $1.57 Million 1738.14%

% of portfolio

0.02%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$7.07 - $45.73 $3.33 Million - $21.5 Million	471,111 Added 240.64%	666,885 $28.8 Million
Q3 2024 Nov 14, 2024	SELL	$7.63 - $9.71 $444,561 - $565,753	-58,265 Reduced 22.94%	195,774 $1.57 Million
Q2 2024 Aug 14, 2024	BUY	$7.84 - $16.79 $1.11 Million - $2.39 Million	142,173 Added 127.09%	254,039 $2.12 Million
Q1 2024 May 15, 2024	BUY	$13.2 - $17.76 $218,790 - $294,372	16,575 Added 17.39%	111,866 $1.99 Million
Q4 2023 Feb 14, 2024	BUY	$6.52 - $20.32 $172,577 - $537,850	26,469 Added 38.46%	95,291 $1.79 Million
Q3 2023 Nov 14, 2023	BUY	$6.02 - $7.76 $54,866 - $70,724	9,114 Added 15.26%	68,822 $488,000
Q2 2023 Aug 14, 2023	BUY	$5.79 - $9.11 $49,157 - $77,343	8,490 Added 16.58%	59,708 $450,000
Q1 2023 May 15, 2023	SELL	$7.36 - $12.72 $268,765 - $464,496	-36,517 Reduced 41.62%	51,218 $409,000
Q4 2022 Feb 14, 2023	SELL	$7.02 - $9.76 $69,834 - $97,092	-9,948 Reduced 10.18%	87,735 $794,000
Q3 2022 Nov 14, 2022	BUY	$5.33 - $11.3 $338,215 - $717,041	63,455 Added 185.39%	97,683 $677,000
Q2 2022 Aug 15, 2022	BUY	$4.66 - $13.96 $159,502 - $477,822	34,228 New	34,228 $188,000

Others Institutions Holding SRRK

# of Institutions

248

Shares Held

88.2M

Call Options Held

1.42M

Put Options Held

1.16M

View Full List

About Scholar Rock Holding Corp

Ticker SRRK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,640,600
Market Cap $1.91B
Description
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clini...

More about SRRK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account